one-hundred and twenty-four patients with primary advanced ( n = 103 ) and recurrent ( n = 21 ) ovarian carcinoma completed a course of platinum-based chemotherapy ( cyclophosphamide/doxorubicin/cisplatin or cyclophosphamide/cisplatin ) or developed progressive disease while on therapy and were evaluated .
C0050385
cyclophosphamide/doxorubicin
C0010583
cyclophosphamide